What are the contraindications to ipratropium bromide nasal spray?

Contraindications to Ipratropium Bromide Nasal Spray

Ipratropium bromide nasal spray is contraindicated only in patients with a history of hypersensitivity to atropine or its derivatives, or to any of the other ingredients in the formulation. 1

Absolute Contraindication

• Hypersensitivity reactions: The only FDA-labeled contraindication is a documented history of allergic reaction to atropine, atropine derivatives, or any component of the ipratropium bromide nasal spray formulation. 1

Important Clinical Considerations (Not Absolute Contraindications)

While the following are not listed as absolute contraindications, they warrant careful clinical consideration:

Glaucoma Patients

• Use with caution in narrow-angle glaucoma: Although ipratropium bromide is a quaternary ammonium compound with poor systemic absorption and minimal systemic anticholinergic effects, anticholinergic medications can theoretically increase intraocular pressure. 2
• Monitor patients with glaucoma for worsening symptoms, though the nasal formulation's local action minimizes this risk compared to systemic anticholinergics. 3, 2

Benign Prostatic Hypertrophy

• Exercise caution in symptomatic BPH: While ipratropium bromide nasal spray acts locally with minimal systemic absorption, patients with symptomatic benign prostatic hypertrophy should be monitored, as systemic anticholinergic effects could theoretically worsen urinary retention. 2
• The poor absorption across biological membranes makes this risk substantially lower than with systemic anticholinergics. 3

Safety Profile Supporting Minimal Contraindications

• Ipratropium bromide is a quaternary structured ammonium compound that is poorly absorbed into systemic circulation from the nasal mucosa, which explains the limited contraindication profile. 3
• The medication does not alter physiologic nasal functions including sense of smell, ciliary beat frequency, mucociliary clearance, or the air conditioning capacity of the nose. 3, 2
• Common adverse effects are mild and local: epistaxis (9% vs 5% placebo) and nasal dryness (5% vs 1% placebo). 2, 4

Clinical Pitfall to Avoid

• Do not confuse with systemic anticholinergics: Unlike tertiary anticholinergic amines, ipratropium bromide's quaternary structure results in minimal systemic anticholinergic effects (neurologic, ophthalmic, cardiovascular, and gastrointestinal), which is why the contraindication list is limited to hypersensitivity only. 3